61 related articles for article (PubMed ID: 8909381)
1. Eltrombopag for use in children with immune thrombocytopenia.
Kim TO; Despotovic J; Lambert MP
Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060
[TBL] [Abstract][Full Text] [Related]
2. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.
Desborough M; Estcourt LJ; Doree C; Trivella M; Hopewell S; Stanworth SJ; Murphy MF
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010982. PubMed ID: 27548292
[TBL] [Abstract][Full Text] [Related]
3. Romiplostim as a treatment for immune thrombocytopenia: a review.
Chalmers S; Tarantino MD
J Blood Med; 2015; 6():37-44. PubMed ID: 25632241
[TBL] [Abstract][Full Text] [Related]
4. Management of thrombocytopenia due to liver cirrhosis: a review.
Hayashi H; Beppu T; Shirabe K; Maehara Y; Baba H
World J Gastroenterol; 2014 Mar; 20(10):2595-605. PubMed ID: 24627595
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy.
Gao L; Li Y; Zhang Y; Chen X; Gao L; Zhang C; Liu Y; Kong P; Wang Q; Su Y; Wang C; Wang S; Li B; Sun A; Du X; Zeng D; Li J; Liu H; Zhang X
Bone Marrow Transplant; 2014 Apr; 49(4):519-24. PubMed ID: 24464145
[TBL] [Abstract][Full Text] [Related]
6. Historical perspective and future directions in platelet research.
Coller BS
J Thromb Haemost; 2011 Jul; 9 Suppl 1(Suppl 1):374-95. PubMed ID: 21781274
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin and hematopoietic stem cells.
de Graaf CA; Metcalf D
Cell Cycle; 2011 May; 10(10):1582-9. PubMed ID: 21478671
[TBL] [Abstract][Full Text] [Related]
8. New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.
Metjian A; Abrams CS
Biologics; 2009; 3():499-513. PubMed ID: 20054440
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin and platelet production in chronic immune thrombocytopenia.
Kuter DJ; Gernsheimer TB
Hematol Oncol Clin North Am; 2009 Dec; 23(6):1193-211. PubMed ID: 19932428
[TBL] [Abstract][Full Text] [Related]
10. Historical review: megakaryopoiesis and thrombopoiesis.
Kaushansky K
Blood; 2008 Feb; 111(3):981-6. PubMed ID: 18223171
[TBL] [Abstract][Full Text] [Related]
11. Molecular control of megakaryopoiesis and thrombopoiesis.
Matsumura I; Kanakura Y
Int J Hematol; 2002 Jun; 75(5):473-83. PubMed ID: 12095146
[TBL] [Abstract][Full Text] [Related]
12. Failing to live up to the fanfare? A personal perspective on obstacles to the clinical development of thrombopoietic agents.
Basser RL; Begley CG
Int J Hematol; 2001 Dec; 74(4):390-6. PubMed ID: 11794693
[TBL] [Abstract][Full Text] [Related]
13. Haemopoietic growth factors in paediatric oncology: a review of the literature.
Wagner LM; Furman WL
Paediatr Drugs; 2001; 3(3):195-217. PubMed ID: 11310717
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin.
Kimura S; Roberts AW; Metcalf D; Alexander WS
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1195-200. PubMed ID: 9448308
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
[TBL] [Abstract][Full Text] [Related]
16. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
[TBL] [Abstract][Full Text] [Related]
17. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
[TBL] [Abstract][Full Text] [Related]
18. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
[TBL] [Abstract][Full Text] [Related]
19. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
Basser RL
Stem Cells; 1998; 16 Suppl 2():225-9. PubMed ID: 11012194
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
